| Name | Title | Contact Details |
|---|
Global Health Strategies (GHS) is an international consulting company that specializes in global health communications, advocacy, research and strategy. We focus on public health issues that impact developing nations and emerging markets. Our clients include leading foundations, industry, NGOs, government agencies, academic institutions and product development. Our work is driven by a passion for improving the health and wellbeing of individuals and communities around the world. We offer the skills, knowledge and goal-driven efficiency to enhance our clients` efforts to address some of the world’s toughest health challenges, including HIV/AIDS, tuberculosis, malaria, polio eradication, sexual and reproductive health and vaccines. GHS has offices in New York, New Delhi, Rio de Janeiro and Beijing, and supports work in countries in Africa, Asia, Europe and the Americas.
Greene County Health Care is a Snow Hill, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Synedgen is a Claremont, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Benchmark Scientific is a Edison, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Increasing Accessibility to Clinical Trials and Personalized Cancer Treatment Options. Every cancer patient is different and deserves treatment of the highest quality that is personalized, affordable, and easily accessible. Massive Bio translates the world-class oncology knowledge of the large cancer centers experts, facilitates a virtual tumor board collaboratively with the treating oncologist, and advises the patient and treating oncologist to operationalize these expert recommendations at the point of care thereby, eliminating additional time, travel, and cost. 85% of US cancer patients receive treatments in community practices where treating oncologists are overwhelmed with the influx of new tests and treatments while trying to manage their busy practices. We believe all cancer patients deserve equal access to the latest in cancer research and treatment.